Molekulargenetische Untersuchungen bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: praktische Relevanz

Schlüsselwörter

nicht-kleinzelliges Bronchialkarzinom - EGFR-Mutation - Tyrosinkinaseinhibitoren - ALK-Translokation - Crizotinib

Keywords

non-small cell lung cancer - EGFR mutation - tyrosinkinase inhibition - ALK translocation - crizotinib

• Literatur

• 1 Bergethon K, Shaw AT, Ou S-HI et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870
• 2 Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019
• 3 Crinó L, Kim D, Riely GJ et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011; 29: #7514
• 4 Davies KD, Le AT, Theodoro MF et al. Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clin Cancer Res 2012; 18: 4570-4579
• 5 Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin-paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874
• 6 Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122-1128
• 7 Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1727-1733
• 8 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388
• 9 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations oft the epidermal growth factor receptor (WJTOG3405): an open label randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128
• 10 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
• 11 Mok T, Kim DW, Wu Y-L et al. First-line crizotinib versus pemetrexed−cisplatin or pemetrexed−carboplatin in patients with advanced ALK-positive non‑squamous non-small cell lung cancer: results of a phase III study (PROFILE 1014). Proc ASCO 2014; #8002
• 12 Ou S-HI, Bang Y-J, Camidge DR et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Proc ASCO 2013; # 8032
• 13 Paz-Ares L, Soulières D, Melezínek I et al. Clinical outcomes in lung cancer patients with EGFR mutations: pooled analysis. J Cell Molec Med 2010; 14: 51-69
• 14 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246
• 15 Sequist LV, Yang JC-H, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334
• 16 Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012
• 17 Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer (PROFILE 1007). N Engl J Med 2013; 368: 2385-2394
• 18 Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012; 30 #7508
• 19 Wu YL, Zhou C, Hu CP et al. LUX Lung 6: A randomized open label, Phase III study of Afatinib versus Gemcitabine/Cisplatin as first line treatment for Asian patients with EGFR mutation positive advanced adenocarcinoma of the lung. Lancet Oncol 2014; 15: 213-222
• 20 Yang JC-H, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3342-3350
• 21 Yang J, Sequist L, Schuler M et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). Proc ASCO 2014; #8004
• 22 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised phase 3 study. Lancet Oncol 2011; 12: 735-42